Author

D. V. Shcheblyakov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

A. L. Gintsburg· 2 shared D. V. Voronina· 2 shared I. A. Favorskaya· 2 shared I. B. Esmagambetov· 2 shared A. A. Derkaev· 1 shared A. A. Iliukhina· 1 shared A. G. Botikov· 1 shared A. I. Korobkova· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. L. Gintsburg

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection

D. V. Voronina, A. S. Bandelyuk, A. S. Dzharullaeva, O. Popova, V. Y. Kan, I. B. Esmagambetov, I. A. Favorskaya, D. V. Shcheblyakov, B. S. Naroditskiy, A. L. Gintsburg

This study modifies two single-domain antibodies to enhance their neutralizing activity against multiple influenza A virus subtypes and demonstrates their protective efficacy in mice.

bioRxiv · Sep 29, 2022 · PreprintImmunology

Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant

I. A. Favorskaya, D. V. Shcheblyakov, I. B. Esmagambetov, I. V. Dolzhikova, I. A. Alekseeva, A. I. Korobkova, D. V. Voronina, E. I. Ryabova, A. A. Derkaev, A. V. Kovyrshina, A. A. Iliukhina, A. G. Botikov, O. L. Voronina, D. A. Egorova, O. V. Zubkova, , A. L. Gintsburg

The paper identifies single-domain antibodies that neutralize SARS-CoV-2 variants, including Omicron, with enhanced potency through dimeric modifications.

bioRxiv · Nov 24, 2021 · PreprintImmunology